Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon

Annese, Virginia; Tomietto, Paola; Venturini, Paolo; D’Agostini, Serena; Ferraccioli, Gianfranco

doi:10.4081/reumatismo.2006.50

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Moreover, it was shown that the presence of Raynaud phenomenon accompanied by classic aPL increases by 2.5 times the probability of having migraine and might be more common in patients with peripheral vasospasm. 31 Thus our study extends these observations suggesting the relationship between migraine and aPS/PT antibodies occurrence.…”

Section: Discussionsupporting

confidence: 85%

Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome

Kopytek

Natorska

Undas

2018

Lupus

View full text Add to dashboard Cite

Objectives Antibodies to phosphatidylserine/prothrombin complex (aPS/PT) detectable in sera of some patients with antiphospholipid syndrome (APS) have been shown to correlate with thrombosis. However, associations of aPS/PT antibodies with APS related disorders remain unclear. Aim To evaluate whether there are any associations between aPS/PT antibodies and Raynaud phenomenon, migraine and/or valvular lesions in primary thrombotic APS (PAPS). Methods We enrolled 67 consecutive patients (56 women) with thrombotic PAPS (VTE in 80.6%), aged 46.2 ± 13.5 years. The exclusion criteria were: acute coronary syndromes or stroke within preceding 6 months, cancer, severe comorbidities and pregnancy. The IgG and IgM aPS/PT antibodies were determined by ELISA with the cut-off of 30 units. We recorded Raynaud phenomenon, migraine and valvular lesions. Results Positive IgM or/and IgG aPS/PT antibodies were observed in 29 patients (43.3%), with a higher prevalence of IgM antibodies ( n = 27, 40.3%) compared with IgG isotype ( n = 12, 17.9%, p = 0.014). aPS/PT antibodies were observed most commonly in patients with triple aPL ( n = 12, 85.7%) compared with those with double ( n = 5, 35.7%) or single aPL antibodies (n = 12, 30.8%, p = 0.03), with no association with demographics, the ANA titre, the type of thrombotic events or medications. Raynaud phenomenon, migraine and valvular lesions were observed in 15% ( n = 10), 30% ( n = 20) and 18% ( n = 12) of the patients, respectively. Raynaud phenomenon and migraine, but not valvular lesions, were markedly more frequent in PAPS patients presenting with positive aPS/PT antibodies ( n = 10, 34.5% vs. n = 0, 0%; p = 0.0001). Conclusions In PAPS patients aPS/PT antibodies are related to the occurrence of both Raynaud phenomenon and migraine.

show abstract

Section: Discussionsupporting

confidence: 85%

Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome

Kopytek

Natorska

Undas

2018

Lupus

View full text Add to dashboard Cite

show abstract

“…It has been already reported [34,35] and, more recently, confirmed [36] also for other types of headache such as migraine, suggesting the potential relevance of perfusion changes in its pathogenesis.…”

Section: Discussionsupporting

confidence: 54%

Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center

et al. 2010

View full text Add to dashboard Cite

To evaluate, by a retrospective cross-sectional case-control study from a single center, the distribution of a number of factors and comorbidities potentially related to central nervous system involvement in SLE Italian patients, a number of "generic" (i.e. not strictly SLE related) and "specific" (i.e. SLE related) risk factors were checked and their distribution analyzed in SLE patients with (NPSLE) and without (SLE) neuropsychiatric (NP) involvement. One hundred and fifty-three SLE patients with NP involvement observed from 1999 to 2008 and 247 SLE patients without NP manifestations, matched for sex, age and disease duration were included in the study. A neuropsychiatric (NP) event represented the heralding symptom of the disease in 40.5% of NPSLE. Headache, cerebrovascular events, mood disorders and seizures were the most frequent NP manifestations. NPSLE patients had a major cumulative number of the investigated factors than controls without NP involvement. Antiphospholipid antibodies (aPL), lupus anticoagulant (LA), Antiphospholipid antibodies syndrome (APS), Raynaud's phenomenon, smoke, assumption of contraceptives and higher cumulative dose of glucocorticosteroids (GC) were significantly more commonly observed among NPSLE. APS and systemic arterial hypertension were more frequently detected among patients with focal NP manifestations, especially cerebrovascular events. aPL, LA, APS, Raynaud's phenomenon, smoke, contraceptives intake and higher cumulative dose of GC did prove more frequently detected in NPSLE patients than in controls. In particular, overall, arterial hypertension should be regarded as a potential independent "risk factor" for focal involvement, especially for cerebrovascular events.

show abstract

“…Further subgroup analysis based on the implementation of migraine diagnosis criteria such as IHS-1988 and ICHD-2004 revealed the prevalence of migraine in SLE patients was 38.2% and 32.1%, respectively (Figure 2). During the literature search, we came across 10 articles 8,9,12,24,26,[30][31][32][33][34] with a prevalence of migraine data but without disclosing the migraine diagnosis criteria. To obtain a worldwide prevalence of migraine in SLE patients, we extended our analysis by considering 27 articles comprising 3473 SLE patients.…”

Section: Worldwide Prevalence Of Migraine In Sle Patientsmentioning

confidence: 99%

Prevalence of migraine in systemic lupus erythematosus: A meta-analysis

Sarangi

Nahak

Rupashree³

et al. 2023

Lupus

View full text Add to dashboard Cite

Background Systemic lupus erythematosus (SLE) is an autoimmune disorder with a wide range of clinical manifestations, including neurological issues in about 25%–75% of cases. Among the neurological involvement cases, most cases show migraine. However, the prevalence of migraine varied worldwide, and in some studies, a higher incidence of migraine in SLE cases was reported compared to healthy controls. In the present study, we adopted a meta-analysis approach to find out the prevalence of migraine in SLE patients worldwide and investigate whether migraine frequency is more prevalent in SLE patients than controls. Material and methods Various literature databases such as Scopus, PubMed, Science Direct, and Google Scholar were screened for eligible studies. The last search was performed on January 21, 2023. Publication biases were accessed by Egger’s regression analysis and funnel plots. Cochrane Q statistics and I2 values explored the presence or absence of heterogeneity. All statistical analysis of meta-analysis was performed in comprehensive meta-analysis software v3. Results Based on predefined inclusion and exclusion criteria, 17 reports comprising 2901 SLE patients and 575 healthy controls were considered in the present study. The meta-analysis revealed the prevalence of migraine to be 34.8%. Furthermore, migraine was more prevalent in SLE patients than healthy controls (OR: 1.964, p = 0.000, 95% CI = 1.512–2.550). Similar trends were also observed while considering another 10 independent reports those were not disclosed about the migraine diagnosis criteria (number of reports: 27, SLE: 3473, HC: 741, prevalence: 33.5%, SLE vs HC: OR = 2.107, p = 0.000, 95% CI = 1.672–2.655). Subgroup analysis demonstrated that SLE patients from South America had a higher prevalence of migraine (56.2%). Conclusions About one-third of SLE patients experience migraine worldwide. The prevalence of migraine is more frequent in SLE patients than the healthy controls.

show abstract

Migraine in SLE: role of antiphospholipid antibodies and Raynaud’s phenomenon

Abstract: L' emicrania è una sindrome frequentemente osservabile in corso di lupus eritematoso sistemico (LES), presentando una prevalenza variabile nelle diverse casistiche tra il 3-56% (1-3). Attualmente non è ancora chiaro in letteratura se essa sia

Cited by 4 publications

References 28 publications

Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome

Antiphosphatidylserine/prothrombin (aPS/PT) antibodies are associated with Raynaud phenomenon and migraine in primary thrombotic antiphospholipid syndrome

Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case–control study from a single center

Prevalence of migraine in systemic lupus erythematosus: A meta-analysis

Contact Info

Product

Resources

About